Impax Laboratories News

Time was running out on Flomax. A key patent protecting the blockbuster drug for treating the symptoms of an enlarged prostate was expiring in little more than a year.

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission has accepted a proposed consent order for public comment relating to Watson's pending acquisition of privately held Arrow Group and has granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction.

IBM announced today that Impax Laboratories, Inc. , a technology-based specialty pharmaceutical company, is using IBM business analytics technology to gain stronger insights into their business and better predict risks and market opportunities.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/30/09, Impax Laboratories, Inc.

Impax Laboratories Inc. confirmed Friday it is challenging the patents on Abbott Laboratories' cholesterol drug TriCor, and that Abbott is suing Impax for patent infringement.

Impax Laboratories, Inc. today announced that it has reached agreement with Astellas Pharma Inc.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Main Category: Urology / Nephrology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 07 Oct 2009 Impax Laboratories, Inc.

HAYWARD,A Calif. A specialty pharmaceutical company announced the tentative approval of its benign prostatic hyperplasia treatment.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Impax Laboratories Inc. , coming off a 3-1/2-year-old patent settlement deal with Shire Pharmaceuticals , launched a generic version of Shire's ADHD drug Adderall XR.

Sep 21, 2009 - Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc.

Main Category: Parkinson's Disease Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 21 Aug 2009 - 1:00 PDT printer friendly view / write opinions rate article OmniComm Systems, Inc.

InvestorSoup.com announces an investment report featuring specialty pharmaceutical company Labopharm Inc.

Jun 15, 2009 - Impax Laboratories, Inc. today announced that the Company's shares were added to the preliminary list of Russell 3000 Index on June 12, 2009.

MILFORD, Conn.-- --DataViz, Inc., a leading provider of Microsoft Office compatibility solutions, today announced the immediate availability of their highly anticipated mobile Office suite application, - BOSTON-- --Eze Castle Integration, Inc., a leading provider of technology and IT services to hedge funds and investment firms, has been recognized ...

Jun 8, 2009 - Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc.

Jun 3, 2009 - Impax Laboratories, Inc. today announced that the Company will present at the Goldman Sachs 2009 Healthcare Conference on Tuesday, June 9th, at 3:45 p.m. Eastern time.

Pennyperformers.com "Penny Stocks that Perform" picks are: Cytokinetics, Incorporated , Epicor Software Corporation , Impax Laboratories, Inc.